Okada S, Yoshimori M, Kakizoe T
Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.
Pancreas. 1998 Apr;16(3):349-54. doi: 10.1097/00006676-199804000-00023.
Although pancreatic cancer (PC) continues to be a formidable disease, numerous treatment strategies are evolving that we hope will result in improved patient survival. To prolong the survival of patients with PC, it is essential to detect PC at the earliest stage possible and to develop effective nonsurgical treatments for this disease. The current strategies for the early diagnosis of PC include the development of diagnostic modalities and screening programs for the early detection of PC and the determination of high-risk groups for PC. K-ras mutations in pancreatic juice obtained endoscopically have been studied recently in association with the early diagnosis of PC, although the interpretation of the presence of a mutated K-ras gene requires caution. The role of the current nonsurgical treatments for PC has been limited. Identification of an effective new chemotherapeutic agent is a high priority, and the enrollment of patients with PC with metastatic disease into well-designed clinical trials is essential. New targets for therapy based on the understanding of the molecular biology of PC may provide avenues for future trials. We must continue to search actively for more accurate methods of diagnosis and more effective methods of treatment for PC.
尽管胰腺癌仍然是一种可怕的疾病，但众多治疗策略正在不断发展，我们希望这些策略能提高患者的生存率。为了延长胰腺癌患者的生存期，尽早发现胰腺癌并开发针对该疾病的有效非手术治疗方法至关重要。目前胰腺癌早期诊断的策略包括开发诊断方法和筛查项目以早期发现胰腺癌，以及确定胰腺癌的高危人群。最近，人们对内窥镜获取的胰液中的K-ras突变与胰腺癌的早期诊断进行了研究，不过对K-ras基因突变的存在进行解读时需要谨慎。目前胰腺癌非手术治疗的作用有限。确定一种有效的新型化疗药物是当务之急，将转移性胰腺癌患者纳入精心设计的临床试验至关重要。基于对胰腺癌分子生物学的理解而确定的新治疗靶点可能为未来的试验提供途径。我们必须继续积极寻找更准确的胰腺癌诊断方法和更有效的治疗方法。
